載入中
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
前收盤價
US$31.81
−US$0.11 · -0.34%
盤中時間採用ET。市場資料可能有所延遲。
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
日內區間
目前US$31.81
52週區間
目前US$31.81
盤中時間採用ET。市場資料可能有所延遲。
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
日內區間
目前US$31.81
52週區間
目前US$31.81
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5402.8萬 USD | 3649.8萬 USD | 2682.3萬 USD | 1424萬 USD | — |
| 銷貨成本 | 1152.2萬 USD | 416.5萬 USD | 950.4萬 USD | 170.4萬 USD | 1877.7萬 USD |
| 毛利 | 4250.6萬 USD | 3233.3萬 USD | 1731.9萬 USD | 1253.6萬 USD | −1877.7萬 USD |
| 研究與開發 | 3.34億 USD | 3.01億 USD | 2.89億 USD | 2.8億 USD | 2.57億 USD |
| 銷售、一般及管理費用 | 1.8億 USD | 1.57億 USD | 1.2億 USD | 1.22億 USD | 1.21億 USD |
| 營業費用 | 5.15億 USD | 4.58億 USD | 4.09億 USD | 4.02億 USD | 3.6億 USD |
| 利息收入 | 5637.9萬 USD | 4808.3萬 USD | 3334.4萬 USD | 1279.3萬 USD | 83.6萬 USD |
| 折舊和攤銷 | 517.7萬 USD | 565.3萬 USD | 662.3萬 USD | 856.4萬 USD | 924萬 USD |
| 營業利益 | −4.72億 USD | −4.26億 USD | −3.91億 USD | −3.89億 USD | −3.78億 USD |
| 淨利 | −4.13億 USD | 6.74億 USD | −3.52億 USD | −2.32億 USD | 16.05億 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI6384.47萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI5511.21萬0.56%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM4959.85萬0.06%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Small-Cap ETFVB4606.46萬0.02%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK2638.55萬0.06%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF2327.92萬0.02%954億 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB1441.27萬0.14%108.2億 USD0.44%US$206.49+3.00%
Dimensional - US Small Cap ETFDFAS1431.39萬0.04%338.69億 USD0.31%US$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
